Description of the medicine: Tetrindolum (Tetrindolum)
TETRINDOL (Tetrindolum). 2, 3, 3, 4, 5, 6-Hexahydro-8-cyclohexyl-1H-pyrazino (3, 2, 1-j, k) carbazole hydrochloride.
Crystalline powder, white with a yellowish or yellowish-greenish tint. It is practically insoluble in water, slightly soluble in alcohol.
In terms of chemical structure, tetrindole is close to pyrazidol and differs by the presence at position 8 of the pyrazinocarbazole nucleus of the cyclohexyl radical instead of the CH3 group.
According to pharmacological properties, tetrindole is close to pyrazidol. It is also a reversible short-acting selective MAO inhibitor of type A. The drug actively inhibits the deamination of norepinephrine and serotonin and, to a lesser extent, tyramine, which virtually eliminates the risk of developing a “cheese” (tyramine) syndrome.
Tetrindol has no anticholinergic effect. Like pyrazidol, it reduces the depriminating effects of reserpine, potentiates the effects of phenamine, L - dopa, 5 - oxytryptophan.
The drug is rapidly absorbed when taken orally, easily penetrates the blood-brain barrier, is found in brain tissues in relatively high concentrations.
An important feature of the therapeutic effect of tetrindole is the rapid onset of effect. Unlike other antidepressants, the effect of which manifests itself after 7 to 10 days and later, the effect of tetrindole is noted after 2 to 3 days from the start of treatment.
In the spectrum of action of tetrindole, a stimulating (psychoenergetic) and actually antidepressant (timoleptic) effect are combined.
The drug is prescribed for depression of various origins: endogenous and psychogenic (reactive, neurotic), depression caused by organic brain damage, and in depressive disorders in patients with chronic alcoholism.
The use of tetrindole is preferable in depressive states of the cyclothymic level (simple melancholic syndrome, asthenic and adynamic disorders, depression with ideative and motor inhibition, depressive disorders with predominantly hypochondriacal symptoms).
In the alcoholism clinic, tetrindole is used for astheno-depressive conditions, adynamic subdepressions occurring with low mood, depression, apathy, increased fatigue in the absence of severe anxiety, insomnia, dysphoric disorders, and outside the period of acute withdrawal.
Tetrindol is prescribed orally in the form of tablets, starting with a dose of 0.025 0.05 g (25 - 50 mg) per dose, 2 times a day (morning and afternoon) with a gradual (within 1 - 2 weeks) dose increase individually, depending on the effectiveness and tolerance up to 0.2 - 0.4 g (200 - 400 mg) per day. The selection of optimal doses, the duration of treatment depend on the nature and course of the disease, the effectiveness and tolerability of the drug.
Tetrindol is usually well tolerated, including by patients of advanced and senile age.